ripertamab
Phase 3Monoclonal antibody
ripertamab is one of 55 small molecule programs targeting Nephrotic Syndrome. It is currently in Phase 3.
3
Indications
3
Total Trials
3
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Nephrotic Syndrome
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Cellcept
RocheApproved
Farxiga
AstraZenecaApproved
Neoral
NovartisApproved
Lovenox
SanofiApproved
Rayos
RRoxane Laboratories
Approved
Aldactone
PfizerApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Thalitone
Jazz PharmaceuticalsApproved
Decadron
AAspen Global Incorporated
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Inflammatory Demyelinating Polyneuropathy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ripertamab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- ZZhongming Qiu